Alexion's Soliris&#0174 (eculizumab) Receives Marketing Approval in Canada for Patients With Atypical HUS

Published: Mar 06, 2013

ONTARIO, March 6, 2013 /CNW/ - Alexion Pharma Canada., a subsidiary of Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), today announced that Canada's national healthcare regulatory agency, Health Canada, has approved the use of SolirisĀ® (eculizumab) for the treatment of patients with atypical hemolytic uremic syndrome (atypical HUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). Atypical HUS, or aHUS, is a life-threatening and chronic ultra-rare, genetic disease that progressively damages vital organs, leading to stroke, heart attack, kidney failure and death.1

Back to news